Can Expired Basaglar Insulin Be Given to Uninsured Patients Who Cannot Afford Insulin?

Direct Answer

No, expired Basaglar (insulin glargine) should not be administered to patients, even those facing financial hardship, because expired insulin may have compromised potency and sterility, potentially leading to inadequate glycemic control and increased infection risk.

Understanding the 28-Day Expiration Standard

Once an insulin glargine vial is punctured, manufacturers recommend discarding it after 28 days due to concerns about both loss of potency and sterility compromise, regardless of whether the vial appears visually unchanged 1.
The FDA-approved labeling for insulin glargine explicitly states that opened vials should be discarded after 28 days, even if insulin remains in the vial 1.
Visual inspection alone is insufficient to determine insulin viability; insulin glargine should appear clear and colorless, but clarity does not guarantee potency beyond the expiration window 2, 1.

Evidence on Extended Use Beyond 28 Days

A Medicaid population study found that 81% of patients used insulin glargine vials beyond the recommended 28-day limit, with a mean duration of 43 days, primarily due to lack of awareness rather than intentional cost-saving measures 3.
The same study revealed that 60% of patients were unaware of the 28-day disposal requirement, and those who were informed learned from pharmacists or diabetes educators 3.
Importantly, this study did not assess clinical outcomes (glycemic control or infection rates) associated with extended use, leaving the safety profile of expired insulin uncertain 3.

Clinical Risks of Using Expired Insulin

Loss of Potency

Insulin stored improperly or used beyond its expiration date may undergo clumping, frosting, precipitation, or changes in clarity/color, all of which indicate loss of potency 2, 1.
Even without visible changes, insulin potency may decline after the vial has been opened for extended periods, leading to unpredictable glucose control and potential hyperglycemic crises 2.
Patients using expired insulin may experience persistent hyperglycemia (glucose >250–300 mg/dL) without recognizing that the insulin itself is ineffective 4.

Sterility Concerns

Repeated needle punctures over extended periods increase the risk of bacterial contamination, which can lead to injection site infections or systemic infections 3.
The FDA labeling warns against using insulin that has been stored improperly or exposed to temperatures outside the range of 36–86°F (2–30°C), as this accelerates degradation 2, 1.

Addressing Insulin Affordability: Evidence-Based Alternatives

Manufacturer Patient Assistance Programs

Uninsured patients may qualify for pharmaceutical patient assistance programs offered directly by insulin manufacturers, which provide free or reduced-cost insulin based on income eligibility 2.
Eligibility criteria vary by state and medication, but these programs are specifically designed to address the affordability crisis for patients without insurance 2.

Human Insulin as a Cost-Effective Alternative

For patients with type 2 diabetes who cannot afford insulin analogs like Basaglar, switching to human insulin (NPH or regular insulin) is a clinically viable and significantly less expensive option 5.
Human insulin costs substantially less than insulin analogs, and while it requires more frequent dosing and carries a slightly higher risk of hypoglycemia, it remains effective for glycemic control when properly titrated 5, 6.
The World Health Organization recommends human insulin as first-line therapy in resource-limited settings, reserving long-acting analogs for patients with frequent severe hypoglycemia 7.

Community Health Centers and Safety-Net Clinics

Federally Qualified Health Centers (FQHCs) and safety-net clinics often provide insulin at reduced cost or through sliding-scale fee structures for uninsured patients 2.
These facilities may also connect patients with pharmaceutical assistance programs and diabetes educators to optimize insulin use 2.

Practical Guidance for Clinicians

Immediate Steps for Patients in Crisis

Do not prescribe or condone the use of expired insulin, as this exposes patients to preventable harm and undermines trust in medical guidance 1.
Assess the patient's current insulin supply: verify expiration dates, storage conditions, and visual appearance of all insulin vials 2, 1.
Initiate contact with manufacturer patient assistance programs immediately, as approval can often be expedited for patients in acute need 2.

Transitioning to Affordable Insulin Regimens

For type 2 diabetes patients, consider switching from Basaglar to NPH insulin (administered twice daily) or regular insulin (administered 30–45 minutes before meals) as a cost-saving measure 5, 6.
Starting doses for NPH insulin are typically 10 units twice daily (before breakfast and dinner), with titration based on fasting and pre-dinner glucose readings 4.
For type 1 diabetes patients, human insulin regimens (NPH + regular insulin) can be used, though they require more frequent monitoring and carry a higher hypoglycemia risk compared to analogs 6, 8.

Patient Education on Insulin Storage and Disposal

Educate patients that opened insulin vials must be discarded after 28 days, even if insulin remains, to ensure potency and sterility 1, 3.
Instruct patients to store unopened vials in the refrigerator (36–46°F) and in-use vials at room temperature (below 86°F), avoiding extreme temperatures 2, 1.
Emphasize that visual inspection alone is insufficient; insulin should be discarded if it appears cloudy, discolored, or contains particles, or if the expiration date has passed 2, 1.

Common Pitfalls to Avoid

Do not assume that expired insulin is "better than nothing"—using ineffective insulin can lead to severe hyperglycemia, diabetic ketoacidosis, or hyperosmolar hyperglycemic state, all of which are life-threatening 4.
Do not delay connecting patients with financial assistance resources; the insulin affordability crisis is well-documented, and multiple safety-net programs exist specifically to address this issue 2, 5.
Do not overlook human insulin as a viable alternative—while insulin analogs offer convenience and slightly lower hypoglycemia rates, human insulin remains effective and is dramatically more affordable for uninsured patients 5, 6.
Do not rely on patient self-reporting of insulin storage practices—directly inspect insulin vials during clinic visits to verify proper storage and expiration dates 9.

Advocacy and Systemic Solutions

Clinicians should advocate for policy changes to address insulin pricing, including support for biosimilar competition, price transparency, and elimination of high-deductible health plans that shift costs to patients 2.
The American Diabetes Association has documented numerous cases of insulin rationing due to cost, leading to preventable hospitalizations and deaths; clinicians must recognize this as a public health crisis requiring systemic intervention 2.
Exempting insulin from health plan deductibles is a critical policy change that would immediately reduce out-of-pocket costs for patients with high-deductible plans 2.

Can expired Basaglar (insulin glargine) be administered to patients who cannot afford insulin and lack insurance?

Help us tailor your experience